

### First generation- (non fluorinated)

Name:	Brand name(s):	Status:
Flumequine	Flubactin, Flumisol, Flumiquil	Withdrawn worldwide
Nalidixic Acid	NegGam, Wintomylon	
Oxolinic Acid	Uroxin	Not approved in U.S.
Pipemidic Acid	Dolcol	Not approved in U.S.
Piromidic Acid	Panacid	
Rosoxacin	Eradacil	Not approved in U.S.

### Second generation

Ciprofloxacin	Cipro, Cipro XR, Ciprobay, Ciproxin, Cetraxal, Ciprodex	
Enoxacin	Enroxil, Penetrex	Withdrawn worldwide
Flexeroxacin	Megaxacin, Roquinol	Withdrawn worldwide
Lomefloxacin	Maxaquin	Removed from market in US
Nadifloxacin	Acuatim, Nadoxin, Nadixa	Not approved in US
Norfloxacin	Lexinor, Noroxin, Quinabic, Janacin	
Ofloxacin	Floxin, Oxaldin, Tarivid	Floxin discontinued
Pefloxacin	Peflacin	
Rufloxacin	Uroflox	

### Third generation

Balofloxacin	Baloxin	
Gatifloxacin	Tequin, Zymar	Withdrawn from market 2006. Hepatotoxicity hypoglycemia and hyperglycemia
Grepafoxacin	Raxar	Withdrawn from the worldwide market by the manufacturer due to adverse cardiac events. 1999
Levofloxacin	Cravit, Levaquin	
Moxifloxacin	Avelox, Vigamox	

Paxufloxacin	Pasil, Pazucross	
Sparfloxacin	Zagam, Megaflox	Withdrawn from most countries 2001, primarily due to lack of sales
Temafloxacin	Omniflox	Withdrawn from market 1992. Hepatotoxicity, acute renal failure, hemolytic anemia, coagulopathy, and hypoglycemia
Tosufloxacin	Ozex, tosacin	

### **Fourth generation**

Besifloxacin	Besivance	
Clinafloxacin		Withdrawn worldwide
Garenoxacin	Geninax	Withdrawn in U.S. and Europe
Gemifloxacin	Factive	
Prulifloxacin	Quisnon	
Sitafloracin	Gracevit	
Trovafloracin	Trovan	Withdrawn worldwide 1999. Risk of hepatic toxicity